Albertsons Companies, Inc.
NYSE•ACI
CEO: Mr. Vivek Sankaran
Sector: Consumer Defensive
Industry: Grocery Stores
Listing Date: 2020-06-26
Albertsons Companies, Inc., through its subsidiaries, engages in the operation of food and drug stores in the United States. The company's food and drug retail stores offer grocery products, general merchandise, health and beauty care products, pharmacy, fuel, and other items and services. It also manufactures and processes food products for sale in stores. It operates stores under various banners, including Albertsons, Safeway, Vons, Pavilions, Randalls, Tom Thumb, Carrs, Jewel-Osco, Acme, Shaw's, Star Market, United Supermarkets, Market Street, Haggen, Kings Food Markets, and Balducci's Food Lovers Market; and pharmacies, in-store branded coffee shops, adjacent fuel centers, distribution centers, and manufacturing facilities, as well as various digital platforms. Albertsons Companies, Inc. was founded in 1860 and is headquartered in Boise, Idaho. Albertsons Companies, Inc. operates as a subsidiary of Albertsons Investor Holdings LLC.
Contact Information
Market Cap
$9.59B
P/E (TTM)
10.7
45.2
Dividend Yield
3.4%
52W High
$23.20
52W Low
$15.80
52W Range
Rank35Top 29.9%
4.6
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 4.6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q3 2025 Data
Revenue
$19.12B+1.86%
4-Quarter Trend
EPS
$0.55-20.29%
4-Quarter Trend
FCF
$1.19B+2115.11%
4-Quarter Trend
2025 Q3 Earnings Highlights
Key Highlights
Identical Sales Growth Identical sales excluding fuel increased 2.4% for the quarter; digital sales grew 21% compared to prior year.
Loyalty Program Expansion Loyalty membership reached 49.8 million members, marking a 12% increase for the third quarter period.
Strong Cash Flow Generation Cash provided by operating activities totaled $1,649.6M for 40 weeks, funding capital investments and debt management.
Capital Allocation Activity Repurchased $1,211.6M in common stock over 40 weeks, including $600.0M initial delivery from ASR agreement.
Risk Factors
Gross Margin Rate Decline Quarterly gross margin rate fell to 27.4% from 27.9%, driven by pharmacy sales mix and digital delivery costs.
Litigation Exposure Remains Ongoing False Claims Act and PBM litigation matters have estimated liabilities recorded; outcomes remain uncertain.
Increased Interest Expense Quarterly interest expense rose to $116.0M from $109.0M due to higher average outstanding borrowings across debt facilities.
Merger Uncertainty Costs Merger-related costs totaled $23.1M this quarter, reflecting ongoing litigation and retention expenses following termination.
Outlook
Technology Investment Focus Technology remains central, enabling rapid AI scaling for speed, intelligence, and personalization across core business functions.
Liquidity Position Maintained Liquidity needs estimated between $5.5B and $6.0B over next 12 months, supported by cash flow and ABL facility.
Debt Structure Optimization Extended ABL maturity to August 2030; issued new notes to redeem $750.0M of existing senior unsecured notes.
Shareholder Returns Commitment Board authorized $2.75B share repurchase program; paid $246.7M in common stock dividends during 40 weeks.
Peer Comparison
Revenue (TTM)
$81.72B
SFM$8.65B
$2.35B
Gross Margin (Latest Quarter)
SFM38.7%
27.4%
26.9%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| ACI | $9.59B | 10.7 | 28.5% | 57.0% |
| SFM | $6.63B | 13.0 | 38.0% | 46.3% |
| VLGEA | $573.47M | 10.3 | 11.4% | 33.1% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
0.6%
Moderate Growth
4Q Net Income CAGR
19.5%
Profitability Improved
Cash Flow Stability
100%
Strong Cash Flow
Research & Insights
Next earnings:Apr 21, 2026
EPS:$0.43
|Revenue:-
Reports
All Years
Form 10-Q - Q3 2025
Period End: Nov 29, 2025|Filed: Jan 7, 2026|Revenue: $19.12B+1.9%|EPS: $0.55-20.3%N/AForm 10-Q - Q2 2025
Period End: Sep 6, 2025|Filed: Oct 14, 2025|Revenue: $18.92B+2.0%|EPS: $0.30+20.0%N/AForm 10-Q - Q1 2025
Period End: Jun 14, 2025|Filed: Jul 22, 2025|Revenue: $24.88B+2.5%|EPS: $0.41-2.4%BeatForm 10-K - FY 2024
Period End: Feb 22, 2025|Filed: Apr 21, 2025|Revenue: $80.39B+1.5%|EPS: $1.65-26.7%MissForm 10-Q - Q3 2024
Period End: Nov 30, 2024|Filed: Jan 8, 2025|Revenue: $18.77B+1.2%|EPS: $0.69+9.5%N/AForm 10-Q - Q2 2024
Period End: Sep 7, 2024|Filed: Oct 15, 2024|Revenue: $18.55B+1.4%|EPS: $0.25-45.7%MissForm 10-Q - Q1 2024
Period End: Jun 15, 2024|Filed: Jul 23, 2024|Revenue: $24.27B+0.9%|EPS: $0.42-41.7%MissForm 10-K - FY 2023
Period End: Feb 24, 2024|Filed: Apr 22, 2024|Revenue: $79.24B+2.0%|EPS: $2.25-1.7%Miss